Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 814

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 814
---
, the “filing” of an NDA shall mean acceptance by the FDA of such NDA for substantive review.

1.50 “MUC16 Program” means WuXi Biologics’ pre-clinical development
program relating to MUC16, as licensed to and further Exploited by Aadi hereunder.

1.51 “Net Sales” means
the sales revenues received by Aadi, its Affiliates and/or Sublicensees, from sales of Licensed Products to Third Party customers, less reasonable and customary deductions for the following items incurred with respect to sales to such customers:

(a) trade, cash and quantity discounts;

(b) price reductions, chargebacks, rebates and allowances, retroactive or otherwise, [***];

(c) amounts repaid or credited by reason of rejections, defects, damaged, outdated or recalled Licensed Products, returned goods
allowance, billing errors, or because of retroactive price reductions, including rebates or wholesaler chargebacks;

G-6

(d) the portion of governmental and other rebates (or the equivalent thereof) paid
during the relevant reporting period [***] relating to such Licensed Product;

(e) fees paid to wholesalers, distributors,
warehousing chains and selling agents [***] with respect to a Licensed Product;

(f) tariffs, taxes, customs duties and other
governmental charges [***] levied on or measured by the billing amount for Licensed Products and actually paid;

(g) freight,
postage, insurance, packing, import/export, and other transportation charges as well as any distribution expenses and fees related to the distribution of such Licensed Product; and

(h) any other similar and customary deductions that are consistent with generally accepted accounting principles.

For clarity, sales of Licensed Products between or among Aadi and its Affiliates and Sublicensees for resale shall be excluded from Net Sales,
but the subsequent resale of Licensed Products shall be included in Net Sales. Transfers, use or sales of Licensed Products for research, Development (including for Clinical Trials), promotional or advertising purposes or as donations or the like or
as “treatment IND sales,” “named patient sales,” “compassionate use sales” or pursuant to any expanded access programs, in each case, shall not be included in Net Sales.

The gross amount received for any Licensed Product included in a Combination Product in a particular Region and during a particular reporting
period shall be calculated by [***].

1.52 “Other Active Ingredient” means any active pharmaceutical
ingredient, which active